Mesenchymal stromal cells for graft-versus-host disease

Area of Science:

• Immunology
• Cell Therapy
• Transplantation Medicine

Background:

• Mesenchymal stromal cells (MSCs) possess immunomodulatory properties.
• Clinical trials have investigated MSC administration for acute graft-versus-host disease (GVHD).
• GVHD is a serious complication following allogeneic hematopoietic cell transplantation.

Purpose of the Study:

• To review the current understanding of MSCs in GVHD treatment.
• To assess the efficacy of MSCs in various GVHD settings.
• To identify future research directions for MSC-based GVHD therapy.

Main Methods:

• Review of existing clinical trial data on MSCs for GVHD.
• Analysis of preliminary studies on de novo, prophylactic, and chronic GVHD.
• Consideration of preclinical findings and animal models.

Main Results:

• Clinical data indicate MSCs benefit approximately two-thirds of patients with steroid-resistant acute GVHD.
• MSCs have been explored for treating de novo acute GVHD, prophylaxis, and chronic GVHD.
• Preclinical data suggested MSCs' role in GVHD mechanisms, but robust models emerged late.

Conclusions:

• MSCs demonstrate therapeutic potential in managing acute GVHD, particularly steroid-resistant cases.
• Further clinical trials are essential to optimize MSC therapy for GVHD.
• Development of advanced animal models and real-time cell tracking is crucial for future advancements.